Central nervous system disease

People who should not work with organophosphate insecticides are those with organic central nervous system disease, mental disorders, epilepsy, pronounced endocrine disorders, respiratory conditions, cardiovascular diseases, circulatory disorders, gastroenteric diseases, liver or kidney disease, and chronic conjunctivitis and keratitis (Medved and Kagan 1983). 

As the rate-limiting enzyme, tyrosine hydroxylase is regulated in a variety of ways. The most important mechanism involves feedback inhibition by the catecholamines, which compete with the enzyme for the pteridine cofactor. Catecholamines cannot cross the blood-brain barrier hence, in the brain they must be synthesized locally. In certain central nervous system diseases (eg, Parkinson s disease), there is a local deficiency of dopamine synthesis. L-Dopa, the precursor of dopamine, readily crosses the blood-brain barrier and so is an important agent in the treatment of Parkinson s disease. 

Glass WG, Lane TE (2003b) Functional expression of chemokine receptor CCR5 on CD4(-l-) T cells during virus-induced central nervous system disease. J Virol 77 191-198 Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM (2005) Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 202 1087-1098... 

Free Rdicals in Central Nervous System Diseases... 

Central nervous system disease Infection Trauma Tumor Vascular... 

Goldberg SH, van der Meer P, Hesselgesser J, et al. CXCR3 expression in human central nervous system diseases. Neuropathol Appl Neurobiol 2001 27 127-138. 

Hiraoka, A., et al (1998). Sodium dodecyl sulfate-capillary gel electrophoretic analysis of molecular mass microheterogeneity of beta-trace protein in cerebrospinal fluid from patients with central nervous system diseases./. Chromatogr. A 802, 143-8. 

Krivit, W., Peters, C. and Shapiro, E. G. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachro-matic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol. 12 167-176,1999. 

In this chapter, 1 tnm hrst to a few additional examples of central nervous system diseases. I begin with two examples that have a clear genetic basis and move on to others for which there is clear genetic disposition bnt an nnclear genetic basis. Later, I will provide some examples—good and bad—of the actions of small molecules on the nervous system. Finally, 1 tnm attention to the issnes of learning and memory. 

Neurologic effects Convulsive seizures and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity, have been reported in patients treated with nitroimidazole drugs including tinidazole and metronidazole. The appearance of abnormal neurologic signs demands the prompt discontinuation of tinidazole therapy. Administer tinidazole with caution to patients with central nervous system diseases. 

The exclusion of organic disease as the cause of a neuropsychiatric syndrome can be difficult. In this context, among other tests, lumbar puncture is indicated because many diseases of the brain are associated with a barrier disorder or an increased cell count. Both findings, sensitive yet nonspecific, are suggestive of central nervous system disease. Apart from these two nonspecific alterations, targeted CSF analysis is an important additional tool, depending on the clinical setting (F4, R6, T2). 

In Chapter 1, John Lowe details The Role of Medicinal Chemistry in Drug Discovery in the twenty first century. The overview should prove invaluable to novice medicinal chemists and process chemists who are interested in appreciating what medicinal chemists do. In Chapter 2, Neal Anderson summarizes his experience in process chemistry. The perspectives provide a great insight for medicinal chemists who are not familiar with what process chemistry entails. Their contributions afford a big picture of both medicinal chemistry and process chemistry, where most of the readers are employed. Following two introductory chapters, the remainder of the book is divided into three major therapeutic areas I. Cancer and Infectious Diseases (five chapters) II. Cardiovascular and Metabolic Diseases (six chapters) and III. Central Nervous System Diseases (four chapters). 

The absence of patients with central nervous system disease or trauma (e.g., previous history of seizures, closed head trauma, or dementia) The limited, if any, experience with hospitalized patients... 

---